Back to search
CD 19+ Acute Leukemia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which CD 19+ Acute Leukemia trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which CD 19+ Acute Leukemia trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells…
The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lym…
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body…